Monday, September 21, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

GLP-1retatrutideeli lillyobesitytriumph-1

Lilly reports bariatric-level weight loss for retatrutide in Phase 3 TRIUMPH-1

The triple agonist's first pivotal readout positions it as Lilly's next obesity candidate behind tirzepatide.

MH
By Maren Holt · Senior Reporter, GLP-1
May 21 03:00 ETSource: Pharmacy Times

The wire

  1. 01Pharmacy Times reports retatrutide delivered bariatric-surgery-level weight loss in the pivotal Phase 3 TRIUMPH-1 trial.
  2. 02A pivotal win for a GIP/GLP-1/glucagon triple agonist would reset the efficacy ceiling clinicians and payers use to compare incretin therapies.
  3. 03Full endpoint data, tolerability and discontinuation rates, and a regulatory filing timeline were not detailed in the item.

From the source

Retatrutide Delivers Bariatric-Level Weight Loss in Pivotal Phase 3 TRIUMPH-1 Trial

Read at pharmacytimes.com
Source URL https://www.pharmacytimes.com/view/retatrutide-delivers-bariatric-level-weight-loss-pivotal-phase-3-triumph-1-trial